390 related articles for article (PubMed ID: 9751783)
1. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
[TBL] [Abstract][Full Text] [Related]
2. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
Tsou HR; Mamuya N; Johnson BD; Reich MF; Gruber BC; Ye F; Nilakantan R; Shen R; Discafani C; DeBlanc R; Davis R; Koehn FE; Greenberger LM; Wang YF; Wissner A
J Med Chem; 2001 Aug; 44(17):2719-34. PubMed ID: 11495584
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
5. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
[TBL] [Abstract][Full Text] [Related]
6. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
[TBL] [Abstract][Full Text] [Related]
8. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.
Xie H; Lin L; Tong L; Jiang Y; Zheng M; Chen Z; Jiang X; Zhang X; Ren X; Qu W; Yang Y; Wan H; Chen Y; Zuo J; Jiang H; Geng M; Ding J
PLoS One; 2011; 6(7):e21487. PubMed ID: 21789172
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
Smaill JB; Showalter HD; Zhou H; Bridges AJ; McNamara DJ; Fry DW; Nelson JM; Sherwood V; Vincent PW; Roberts BJ; Elliott WL; Denny WA
J Med Chem; 2001 Feb; 44(3):429-40. PubMed ID: 11462982
[TBL] [Abstract][Full Text] [Related]
10. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
Discafani CM; Carroll ML; Floyd MB; Hollander IJ; Husain Z; Johnson BD; Kitchen D; May MK; Malo MS; Minnick AA; Nilakantan R; Shen R; Wang YF; Wissner A; Greenberger LM
Biochem Pharmacol; 1999 Apr; 57(8):917-25. PubMed ID: 10086326
[TBL] [Abstract][Full Text] [Related]
11. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases.
Denny WA
Farmaco; 2001; 56(1-2):51-6. PubMed ID: 11347967
[TBL] [Abstract][Full Text] [Related]
12. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
Vincent PW; Bridges AJ; Dykes DJ; Fry DW; Leopold WR; Patmore SJ; Roberts BJ; Rose S; Sherwood V; Zhou H; Elliott WL
Cancer Chemother Pharmacol; 2000; 45(3):231-8. PubMed ID: 10663641
[TBL] [Abstract][Full Text] [Related]
13. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
14. Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
Gaul MD; Guo Y; Affleck K; Cockerill GS; Gilmer TM; Griffin RJ; Guntrip S; Keith BR; Knight WB; Mullin RJ; Murray DM; Rusnak DW; Smith K; Tadepalli S; Wood ER; Lackey K
Bioorg Med Chem Lett; 2003 Feb; 13(4):637-40. PubMed ID: 12639547
[TBL] [Abstract][Full Text] [Related]
15. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor.
Ward WH; Cook PN; Slater AM; Davies DH; Holdgate GA; Green LR
Biochem Pharmacol; 1994 Aug; 48(4):659-66. PubMed ID: 8080438
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.
Tanaka H; Hirata M; Shinonome S; Wada T; Iguchi M; Dohi K; Inoue M; Ishioka Y; Hojo K; Yamada T; Sugimoto T; Masuno K; Nezasa K; Sato N; Matsuo K; Yonezawa S; Frenkel EP; Shichijo M
Cancer Sci; 2014 Aug; 105(8):1040-8. PubMed ID: 24837299
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors against EGF receptor-positive malignancies.
Sudbeck EA; Ghosh S; Liu XP; Zheng Y; Myers DE; Uckun FM
Methods Mol Biol; 2001; 166():193-218. PubMed ID: 11217368
[No Abstract] [Full Text] [Related]
19. Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
Hur W; Velentza A; Kim S; Flatauer L; Jiang X; Valente D; Mason DE; Suzuki M; Larson B; Zhang J; Zagorska A; Didonato M; Nagle A; Warmuth M; Balk SP; Peters EC; Gray NS
Bioorg Med Chem Lett; 2008 Nov; 18(22):5916-9. PubMed ID: 18667312
[TBL] [Abstract][Full Text] [Related]
20. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
Cockerill S; Stubberfield C; Stables J; Carter M; Guntrip S; Smith K; McKeown S; Shaw R; Topley P; Thomsen L; Affleck K; Jowett A; Hayes D; Willson M; Woollard P; Spalding D
Bioorg Med Chem Lett; 2001 Jun; 11(11):1401-5. PubMed ID: 11378364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]